Sai Parenteral’s Limited is a pharmaceutical formulations company engaged in research, development and manufacturing of medicines. The company operates through two key verticals: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services for domestic and international markets. Its product portfolio covers therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, analgesics and dermatology. These medicines are supplied in various dosage forms including injectables, tablets, capsules, liquid orals and ointments. The company earns revenue by selling its branded generics to hospitals, government agencies, pharmaceutical companies and distributors, while also providing CDMO services such as product development, regulatory filings and commercial manufacturing for global clients.

The Company is led by Promoter, ANIL KUMAR KARUSALA, VIJITHA GORREPATI AND KARUSALA ARUNA

The Revenues frorom operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 894.27 Million, ₹ 1,637.43 Million, ₹ 1,551.80 Million, and ₹ 970.28 Million, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 162.36 Million, ₹ 394.35 Million, ₹ 317.00 Million, and ₹ 176.41 Million, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 77.64 Million, ₹ 144.54 Million, ₹ 84.15 Million, and ₹ 43.76 Million, respectively. This indicates a steady growth in financial performance.

 The Company Key Performance Indicates the pre-issue EPS of ₹ 5.43  and post-issue EPS of ₹ 3.27 for FY25. The pre-issue P/E ratio is 72.19x,while the post-issue P/E ratio is 119.82x against the Industry P/E ratio is 62.29x The company's ROE for FY25 is 16.82% and RoNW is 15.09% The Annualised EPS is ₹ 3.51x and P/E is ₹ 111.53x  , These metrics suggest that the IPO is Fully priced.

The Grey Market Premium (GMP) of Sai Parenteral’s showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Sai Parenteral’s Limited. IPO for Listing gain or Long Term Purposes.